One possible interpretation of our data is that CDKN1B amplification in primary tumors acts to slow the rate of tumor proliferation and metastasis, which would point toward the possible utility of CDK4/6 inhibitors as a means of delaying progression to metastatic disease. Here, CDKN1B is linked to metastatic neoplasm.